this comes up almost weekly in threads i read, and the framing is usually wrong in a way that matters, so here’s the version i’d want a patient to have before they signed up for anything compounded. there are two completely different categories of compounding pharmacy in the US, and people use the word “compounded” as if it’s one thing. it isn’t. 503a pharmacies compound for an individual patient pursuant to a valid prescription. they’re regulated primarily by state boards of pharmacy, with FDA oversight on a narrower set of issues. they are not permitted to compound “essentially a copy” of a commercially available drug, with some narrow exceptions, one of which is when the FDA-approved version is on the drug shortage list. that shortage exception is exactly the door that opened for compounded semaglutide and tirzepatide between roughly 2022 and 2024. when the shortages resolved, the door closed, and the FDA gave a wind-down window for enforcement discretion. that window ending is not a ban on compounding, it’s the return to the baseline rule that already existed. 503b outsourcing facilities are a different animal. they register with the FDA, follow cGMP (current good manufacturing practice) standards similar in spirit to a manufacturer, can compound in bulk without patient-specific prescriptions, and are inspected differently. their sterility assurance, environmental monitoring, and beyond-use dating are held to a much higher bar than a 503a. practically, what this means when you’re evaluating a vendor: - if someone is selling you a “compounded” tirzepatide right now, ask which category. if they can’t tell you, that’s your answer.
ask what API (active pharmaceutical ingredient) they’re using. semaglutide sodium and semaglutide base are not the same molecule and the data on the salt form in humans is essentially absent. the branded products are the base.
ask for the beyond-use date and the basis for it. usp 797 sets the framework. “good for 90 days in the fridge” without a sterility study behind it is somebody guessing.
ask whether the finished product was tested for potency, sterility, and endotoxin, not just the raw material’s certificate of analysis. those are different tests answering different questions. branded products from Novo and Lilly have their own issues, cost being the obvious one, but the manufacturing controls are not in question. compounded products can be appropriate, especially for documented clinical reasons like a true allergy to an inactive ingredient, but “it’s cheaper” was never a legal basis under 503a and it isn’t one now. ask the questions. a pharmacy that resents being asked is telling you something.
the 503b ceiling is real, but “much higher bar” smooths over a pretty consistent track record of 483s and warning letters - that doesn’t happen to facilities actually clearing the bar. the sema sodium vs base point is well taken; that distinction matters more than most patients ever think to ask about. where the post loses me is the BUD framing. “usp 797 sets the framework” is accurate, but the 2023 revision changed sterility testing requirements and BUD calculation methodology in ways a lot of 503a compounders haven’t fully absorbed. when a pharmacy quotes you a 90-day BUD and says it’s grounded in usp 797, the question that actually matters is which version they’re working from. the new standards require sterility testing to support Category 2 dating in a way the old framework didn’t mandate, and plenty of compounders are still citing the old rules. that’s a narrower gap than the rest of what you laid out, but it’s real, and it’s exactly the kind of thing patients don’t know to ask.
“those are different tests answering different questions” is the line worth emphasizing. from the compounding side, it’s common to have a solid API COA and essentially nothing on the finished vial itself, no sterility, no endotoxin, no potency confirmation on what actually shipped.
fair pushback, and you’re right that i collapsed the version question into the framework citation. the 2023 chapter revisions are in effect, and Category 2 CSPs require sterility testing to support the longer BUDs in a way the 2008 framework didn’t. so when a 503a quotes 90 days refrigerated for an aqueous peptide, the right follow-up is “category 1 or 2, and where’s the sterility data supporting category 2 dating.” plenty of compounders are still operating off muscle memory from the old chapter, or they revised their sops on paper without actually validating to the new requirements. that’s the gap worth pressing on.
“revised their SOPs on paper without actually validating to the new requirements” is the exact gap, and the harder follow-up worth asking is whether they can point you to the specific sterility study that underpins the BUD on your batch, not just a policy document that says they’ve adopted the 2023 framework.
treating “503b” as a proxy for “clean” is where this post loses me slightly. the regulatory distinction is real and matters, the cGMP requirements and FDA registration aren’t nothing. but “held to a higher bar” and “actually meeting the higher bar” are different things. the FDA sent warning letters to multiple outsourcing facilities through 2024-2025 for cGMP deficiencies in their sterile compounding lines, and a notable chunk of those were facilities that had jumped into the sema/tirz market specifically. so “ask which category” is the right first question, but it can’t be the last one. the follow-up is whether the 503b you’re looking at has a recent FDA inspection record you can actually pull, and what it said. warning letters are public. 483 observations are public. a facility that’s uncomfortable w/ “can you point me to your last inspection summary” is giving you exactly the same tell the post described for pharmacies that resent questions. the tier matters, but the tier isn’t the whole answer.
the 503a vs 503b framing is the right starting point and the category question is genuinely the first thing to ask, but for most patients sourcing through telehealth right now the answer is going to be 503a basically every time, so the practical version of your checklist (BUD basis, finished-product testing, API source) is doing more work than the binary itself. the part i’d push on is “data on the salt form in humans is essentially absent.” that was true two years ago, it’s less true now. there’s a couple years of real-world exposure on semaglutide sodium across what has to be hundreds of thousands of patients via compound, and while that’s not a trial and it won’t catch low-frequency AEs, it’s not nothing. the honest version is the salt form lacks controlled trial data, not that it lacks exposure data, those are different problems with different interpretive limits. headline absence-of-evidence reads stronger than what the situation actually is. one i’d add to your list, for the in-use vial side specifically: dose number within the vial. sealed BUD and in-use BUD are different curves, and compounded sema without polysorbate 80 (week 18 here, that’s my window) has a different degradation profile than the pen formulations most stability talk is built on. the stopper gets punctured a dozen+ times, preservative load drops, and “good for 90 days in the fridge” starts doing the most uncertain work on doses 8, 9, 10. i’ve been logging dose number alongside food noise and side effects with a short note per entry, partly because the late-vial doses are where i suspect something’s hiding if it’s hiding anywhere. clear doesn’t mean potent, agreed on that one fully.
The point about asking for the basis behind the BUD is the one that changed how I read my own paperwork. I went back to my pharmacy around week 6 and asked exactly that, and what I got back was the API certificate of analysis and a USP 797 reference, not a sterility study on the finished product. They weren’t defensive about it, they were upfront that the BUD was set off the framework rather than a vial-specific study, and that’s a different answer than “we tested this batch.” Which I think your closing line gets at really well, the willingness to answer the question is the actual signal more than the answer itself. The piece I’d add for anyone reading and trying to act on this is that once the vial is in your fridge and you’ve punctured the stopper a handful of times, the risk profile shifts again, and that’s the part that doesn’t show up in any of the documents the pharmacy will hand you. Sterility and degradation are doing different work in those questions, and the degradation curve on compounded sema without polysorbate 80 isn’t the same shape as what most of the pen-formulation stability chatter assumes. I started logging the dose number within each vial alongside my weekly weight in CareClinic just so I’d have something to look back at if a late-vial dose ever correlates with anything odd. The daily check-in takes maybe 40 seconds and having vial-dose-number sit right next to food noise score has made the retrospective patterns more legible than I expected. Genuine question back at you, do you have a sense of whether finished-product testing for potency, sterility and endotoxin is something a reasonably reputable 503a will run per batch in practice, or is that essentially a 503b-only expectation in the real world? I’ve had conflicting answers from two different pharmacies and I don’t quite know what to weight.
the 503b framing here is solid but the “held to a much higher bar” language flattens something important. registered w/ FDA and actually compliant w/ cGMP are two different claims, and the FDA has sent warning letters to multiple outsourcing facilities for sterility and environmental monitoring deficiencies. so treating 503b registration as a quality proxy gets you most of the way there but not all of it. reading the inspection database is a step most people skip.
the 503a/503b split is the right frame and most patient threads do conflate them, but “held to a much higher bar than a 503a” is doing more work than the inspection record supports. the regulatory framework is more rigorous on paper, that part is true. in practice you have to pull the FDA inspection history for the specific facility, 483s on 503bs over the last few years have included some pretty serious sterility and environmental findings, and “registered as a 503b” isn’t the same claim as “consistently meets the bar 503b is supposed to meet.” the framework promises more, execution is facility-specific, and a 503a with a clean state board record and a real stability program can in practice outperform a 503b with a recent warning letter. so the category tells you what to ask, not what you’re getting. the other piece i’d add to the finished-product testing list: identity and related substances. potency, sterility, and endotoxin are the three you named, all important, but identity confirms the molecule is what the label says (not just present at the right concentration), and the related-substances assay picks up degradants and process impurities that a potency number won’t flag. when you ask for a finished-product CoA most 503as will hand you potency and sterility and call it complete, the actual gap in those packets is almost always identity and the impurity profile. beyond that the framing’s solid, “a pharmacy that resents being asked is telling you something” is the right line to leave people with.